Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

35.95
-0.4188-1.15%
Volume:143
Turnover:5K
Market Cap:18.87M
PE:- -
High:35.95
Open:35.39
Low:35.39
Close:36.37
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:3.16
T/O Rate:0.03%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

UnitedHealth price target lowered to $402 from $430 at TD Cowen

TIPRANKS
·
22 mins ago

U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines

Reuters
·
1 hour ago

Piper Sandler recommends buying UnitedHealth on 2027 Star Ratings release

TIPRANKS
·
1 hour ago

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026

TIPRANKS
·
1 hour ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
1 hour ago

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
1 hour ago

Teva announces FDA approval for Weltruza

TIPRANKS
·
1 hour ago

Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint

TIPRANKS
·
1 hour ago

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
1 hour ago

Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System

Stock News
·
1 hour ago

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
1 hour ago

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
1 hour ago

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
1 hour ago

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

GlobeNewswire
·
1 hour ago

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

GlobeNewswire
·
1 hour ago

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
2 hours ago

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
2 hours ago

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
2 hours ago

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
2 hours ago

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
2 hours ago